Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase

References

• World Health Organization. Hepatitis C key facts. 2020 [cited 2020 Sep 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
   Google Scholar
• Centers for Disease Control and Prevention. Viral Hepatitis Surveillance – United States, 2018 Atlanta (GA): 2020 [cited 2020 Sep 4]. https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm
   Google Scholar
• AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2022 [cited 2023 Jul 5]. Available from: https://www.hcvguidelines.org/
   Google Scholar
• Childs K, Davis C, Cannon M, et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C. J Hepatol. 2019;71(6):1099–105. doi: 10.1016/j.jhep.2019.07.025
   PubMed Web of Science ®Google Scholar
• Fourati S, Rodriguez C, Hezode C, et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology. 2019;69(2):513–23. doi: 10.1002/hep.30225
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines mavyret, zepatier, and vosevi in some patients with advanced liver disease. 2019 [cited 2020 Sep 3]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and
   Google Scholar
• Cursino CN, Monteiro PGO, Duarte GDS, et al. Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C. Pharmacoepidemiol Drug Saf. 2019;28(12):1601–8. doi: 10.1002/pds.4904
   PubMed Web of Science ®Google Scholar
• Itakura J, Kurosaki M, Kakizaki S, et al. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Rep. 2020;2(5):100138. doi: 10.1016/j.jhepr.2020.100138
   PubMedGoogle Scholar
• Costantino A, Spada E, Equestre M, et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J. 2015;12(1):186.
   PubMedGoogle Scholar
• Gane EJ, Metivier S, Nahass R, et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun. 2017;1(6):538–49. doi: 10.1002/hep4.1060
   PubMed Web of Science ®Google Scholar
• Uchida Y, Kouyama JI, Naiki K, et al. “Reversi-type virologic failure” involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017;47(13):1397–1407. doi: 10.1111/hepr.12882
   PubMed Web of Science ®Google Scholar
• Good SS, Moussa A, Zhou XJ, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020;15(1):e0227104.
   PubMed Web of Science ®Google Scholar
• Berliba E, Bogus M, Vanhoutte F, et al. Safety, pharmacokinetics and antiviral activity of AT- 527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019;63(12):e01201–19.
   PubMed Web of Science ®Google Scholar
• Mungur O, Berliba E, Bourgeois S, et al. A combination of AT-527, a potent pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects. London (UK): The International Liver Congress; [cited 2020 Aug 27-29]. Available from: https://easl.eu/event/the-digital-international-liver-congress-2020/
   Google Scholar
• Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int. 2013;33(Suppl 1):85–92. doi: 10.1111/liv.12068
   PubMedGoogle Scholar
• Ehteshami M, Tao S, Ozturk T, et al. Biochemical characterization of the active anti-hepatitis C virus metabolites of 2,6- diaminopurine ribonucleoside prodrug compared to sofosbuvir and BMS-986094. Antimicrob Agents Chemother. 2016;60(8):4659–4669. doi: 10.1128/AAC.00318-16
   PubMed Web of Science ®Google Scholar
• Gill M, Horn K, Hennan J, et al. Investigative nonclinical cardiovascular safety and toxicology studies with BMS-986094, an NS5b RNA-dependent RNA polymerase inhibitor. Toxicol Sci. 2017;155(2):348–362.
   PubMed Web of Science ®Google Scholar
• Coats SJ, Garnier-Amblard EC, Amblard F, et al. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res. 2014;102:119–147. doi: 10.1016/j.antiviral.2013.11.008
   PubMed Web of Science ®Google Scholar
• Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low- level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209(5):668–75. doi: 10.1093/infdis/jit562
   PubMed Web of Science ®Google Scholar
• Huang Q, Good SS, Cai D, et al. Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination. Poster 1861-A. Presented at the American Association for the Study of Liver Diseases 2023 Annual Meeting, 2023 Nov 10-14, Boston (USA).
   Google Scholar
• Good S, Westover J, Jung KH, et al. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021;65(4):e02479–20.
   PubMed Web of Science ®Google Scholar
• Dittmar M, Whig K, Miller J, et al. Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus. PNAS Nexus. 2023;2(9):1–8.
   Google Scholar
• Feng JY, Xu Y, Barauskas O, et al. Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus. Antimicrob Agents Chemother. 2016;60(2):806–817.
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Berliba E, Bogus M, et al. AT-527, a purine nucleotide prodrug, exhibits potent pan-genotypic antiviral activity in HCV-infected subjects with cirrhosis. The Liver Meeting; 2018 Nov 9-13;San Francisco (CA). https://ateapharma.com/wp-content/uploads/2020/08/48X72LandscapeAASLD201820181023final.pdf
   Google Scholar
• Zhou XJ, Berliba E, Jucov A, et al. HCV viral kinetic analysis predicts shorter treatment duration with AT- 527, a purine nucleotide prodrug with potent pan-genotypic antiviral activity in HCV-infected subjects regardless of cirrhosis status. The Liver Meeting; 2019 Nov 8-12; Boston (MA). https://ateapharma.com/wp-content/uploads/2020/08/48X72LandscapeAASLD2019VKFinal.pdf
   Google Scholar
• Zhou XJ, Berliba E, Vanhoutte F, et al. AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C. The International Liver Congress; 2018 Apr 11-15; Paris (France). https://ateapharma.com/wp-content/uploads/2020/08/90cmX140cmLandscapeEASL201820180406final.pdf
   Google Scholar
• Zhou XJ, Vanhoutte F, Berliba E, et al. A phase 1a study of AT-527, a novel pan- genotypic purine nucleotide prodrug inhibitor of hepatitis C virus (HCV). The Liver Meeting; 2017 Oct 20-24; Washington (D.C). https://ateapharma.com/wp-content/uploads/2020/08/36x60HorizontalTemplatev12Atea-Pharmaceuticals-AASLDFinal20171020.pdf
   Google Scholar
• Graf C, Welzel T, Bogdanou D, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis. JCM. 2020;9(9):2702.
   Google Scholar
• Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One. 2016;11(9):e0163644.
   PubMed Web of Science ®Google Scholar
• Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther. 2014;19(2):211–20. doi: 10.3851/IMP2733
   PubMed Web of Science ®Google Scholar
• Perelson AS, Guedj J. Modelling hepatitis C therapy–predicting effects of treatment. Nat Rev Gastroenterol Hepatol. 2015;12(8):437–445. doi: 10.1038/nrgastro.2015.97
   PubMed Web of Science ®Google Scholar
• De Clercq E, Schinazi RF. Editorial overview: antiviral strategies. Curr Opin Virol. 2016;18:v–vi. doi: 10.1016/j.coviro.2016.06.005
   PubMed Web of Science ®Google Scholar
• Furman PA, Murakami E, Niu C, et al. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res. 2011;91(2):120–32. doi: 10.1016/j.antiviral.2011.05.003
   PubMed Web of Science ®Google Scholar
• Niu C, Tolstykh T, Bao H, et al. Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Antimicrob Agents Chemother. 2012;56(7):3767–75. doi: 10.1128/AAC.00530-12
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599–607. doi: 10.1056/NEJMoa1512610
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17. doi: 10.1056/NEJMoa1512612
   PubMed Web of Science ®Google Scholar
• Good SS, Lin K, Luo S, et al. The combination of bemnifosbuvir (BEM) and Ruzasvir (RZR), the HCV NS5B and NS5A inhibitors, demonstrates potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions. Poster 411. Presented at the International Conference on Antiviral Research; 2023 Mar 13-17; Lyon (France).
   Google Scholar
• Tong L, Yu W, Chen L, et al. Discovery of ruzasvir (MK-8408): a potent, Pan-genotype HCV NS5A Inhibitor with optimized activity against common resistance-associated polymorphisms. J Med Chem. 2017;60(1):290–306. doi: 10.1021/acs.jmedchem.6b01310
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Feld JJ, et al. C-BREEZE-2 study investigators. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. J Viral Hepat. 2019;26(9):1127–1138. doi: 10.1111/jvh.13132
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Morelli G, Montrond M, et al. Lack of pharmacokinetic drug-drug-interaction between bemnifosbuvir and ruzasvir in healthy participants. Poster 1879. Presented at the Liver Meeting; 2023 Nov 10-14; Boston (MA, USA).
   Google Scholar